Efficacy and Safety of Combined Therapy with 89Sr in Skeletal-Related Events of Prostate Cancer:A Meta-analysis
10.3870/j.issn.1004-0781.2017.12.019
- VernacularTitle:联合89锶治疗前列腺癌骨相关事件有效性及安全性Meta分析
- Author:
Liangliang LI
1
;
Xiaoqiang REN
;
Ziran XU
;
Shiyong XIN
;
Jianguo ZHANG
Author Information
1. 河南科技大学第一附属医院泌尿外科
- Keywords:
89Sr;
Cancer;
prostate;
Skeletal-related events;
Systematic review;
Controlled trial;
randomized
- From:
Herald of Medicine
2017;36(12):1404-1410
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficacy and safety of combined therapy with 89Sr for treating skeletal-related events of prostate cancer. Methods Databases including PubMed,MEDLINE,EMBASE,the Cochrane library,CNKI,CBM and Wanfang were systematically searched since 89Sr was first reported in 1976 to September 2015 to include the randomized controlled trials (RCTs) of the combined therapy with 89Sr for skeletal-related events of prostate cancer.The statistical analysis was performed using Review Manager Version 5.2. Results A total of 18 RCTs involving 1 280 patients were analyzed.The results of meta-analysis indicated:there were statistically significant differences in the pain relief rate [OR=4.71,95%CI(3.34, 6.62),P<0.000 1],decrement rate of bone metastasis[OR=3.63,95%CI(2.60,5.09),P<0.000 1] and improvement rate of life quality [OR=2.16,95%CI(1.16,4.02),P<0.05].Progression-free survival of patients in experimental group was significantly longer than that in control group [HR=0.84,95%CI(0.73,0.97),P=0.02].No significant difference was found in overall survival [HR=0.82,95%CI(0.65,1.02),P=0.07].There were no significant differences in the incidence of adverse events [OR=1.46,95%CI(0.98,2.17),P>0.05]. Conclusion Combined therapy with 89Sr has better efficacy and comparable safety profile compared with standard therapy.However,the quality and sample size of the included studies are limited,so more high-quality and large-sample RCTs are needed to verify the validity.
